BriaCell Therapeutics - Warrants (24/02/2025) Receivables

As of the most recent data (April 2026), BCTXW shows a receivables of $2.6M. That compares with $2.3M in the prior-year period — up 11.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCTXW's receivables is now $2.6M (was $2.3M) — a 11.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether BriaCell Therapeutics - Warrants (24/02/2025) is outperforming or lagging.

Tracking BCTXW's receivables over time shows whether BriaCell Therapeutics - Warrants (24/02/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $2.6M That compares with $2.3M in the prior-year period — up 11.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has BriaCell Therapeutics - Warrants (24/02/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $2.6M) with ownership activity and broader fundamentals.

BriaCell Therapeutics - Warrants (24/02/2025)'s receivables is $2.6M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.